Remicaide (infliximab)

Phase 2Monoclonal antibody

Remicaide (infliximab) is one of 9 small molecule programs targeting Toxic Epidermal Necrolysis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Toxic Epidermal NecrolysisActive, not recruiting

Toxic Epidermal NecrolysisPhase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Toxic Epidermal Necrolysis

#DrugCompanyPhaseTrials

Recombinant Granulocyte Colony-Stimulating Factor

FFred Hutchinson Cancer Center

Approved

1 2

Immunoglobulin

Sanofi

Phase 3

1 3

Darzalex

Johnson & Johnson

Phase 2

1 4

Remicade

OOrganon and Co

Phase 2

1 5

Cibinqo

Pfizer

Phase 1

1 6

Kepivance

SSwedish Orphan Biovitrum

Phase 1

1 7

Xeljanz

PPrism Pharmaceuticals

Phase 1

1 8

Accutane

CConrado Roberto Hoffmann Filho

Preclinical

—9

Remicaide (infliximab)

LLoyola University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Toxic Epidermal Necrolysis1 trial

Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)

Withdrawn·LLoyola University·Phase 2·NCT00372723

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Remicaide (infliximab). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Remicaide (infliximab) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Remicaide (infliximab). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Loyola University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: LLoyola University

Remicaide (infliximab)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Toxic Epidermal Necrolysis1 trial

References

Drug Info

Quick Facts

Related News